Equities

Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd

Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)2.35
  • Today's Change0.04 / 1.73%
  • Shares traded1.50k
  • 1 Year change+32.77%
  • Beta0.7927
Data delayed at least 10 minutes, as of Nov 14 2024 02:13 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of CNY
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments2,0592,7522,768
Total Receivables, Net2,6872,7852,011
Total Inventory1,5671,4291,525
Prepaid expenses----121
Other current assets, total239279--
Total current assets6,5527,2456,425
Property, plant & equipment, net1,4421,4651,486
Goodwill, net6685--
Intangibles, net798820
Long term investments1,518816756
Note receivable - long term------
Other long term assets564642
Total assets10,23010,1579,067
LIABILITIES
Accounts payable1,1261,4061,242
Accrued expenses260216145
Notes payable/short-term debt01020
Current portion long-term debt/capital leases854.101.60
Other current liabilities, total1,7551,5761,013
Total current liabilities3,2263,3042,402
Total long term debt2441521.57
Total debt3292583.17
Deferred income tax7.338.824.21
Minority interest4530149
Other liabilities, total101111114
Total liabilities3,6223,6062,671
SHAREHOLDERS EQUITY
Common stock770773773
Additional paid-in capital1,2071,2291,229
Retained earnings (accumulated deficit)4,6394,5574,395
Treasury stock - common------
Unrealized gain (loss)(8.37)(8.41)(0.32)
Other equity, total------
Total equity6,6086,5516,397
Total liabilities & shareholders' equity10,23010,1579,067
Total common shares outstanding770773773
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.